Study guide

9.2 Pleural Effusion & Pneumothorax

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

9.2 Pleural Effusion & Pneumothorax

Key Takeaways Explain This Topic AI

Pleural effusions are categorized as transudates (protein <30 g/L; driven by systemic imbalances in hydrostatic or oncotic pressure) or exudates (protein >30 g/L; driven by local inflammation, infection, or malignancy); borderline effusions (protein 25–35 g/L) mandate evaluation using Light's criteria.

According to Light's criteria, an effusion is an exudate if it meets any one of three parameters: pleural/serum protein ratio >0.5, pleural/serum LDH ratio >0.6, or pleural LDH > two-thirds the upper limit of normal serum LDH.

A pleural fluid pH <7.2 in the setting of a parapneumonic effusion indicates a complicated effusion or frank empyema, representing an absolute indication for urgent tube thoracostomy (chest drain) drainage.

BTS guidelines differentiate primary spontaneous pneumothorax (PSP; no underlying lung disease) from secondary spontaneous pneumothorax (SSP; pre-existing lung pathology, age >50, smoking history); SSP with a rim >2 cm or dyspnoea warrants immediate small-bore chest tube insertion rather than simple aspiration.

Diving is permanently contraindicated following a spontaneous pneumothorax unless bilateral surgical pleurectomy has been performed; commercial flying must be avoided until at least 1 to 2 weeks after complete radiographic re-expansion.

Last updated: September 2026

Pleural pathology represents one of the most heavily assessed clinical domains in MRCP(UK) Part 1. Candidates are expected to seamlessly integrate pleural fluid biochemistry using Light's criteria, identify specific indicators for urgent chest tube drainage, and correctly apply the British Thoracic Society (BTS) management guidelines for primary versus secondary pneumothoraces.

1. Pleural Effusion: Transudates vs Exudates

The pleural space normally contains 0.1–0.2 mL/kg (~10–15 mL) of sterile fluid that lubricates the parietal and visceral pleura. Fluid is continuously filtered across parietal pleural microvessels and absorbed by parietal stomata into the lymphatic drainage network. An effusion develops when fluid filtration overwhelms lymphatic clearance.

General Classification by Protein Concentration

Gross Differentiation: Pleural fluid total protein <30 g/L indicates a transudate ; pleural protein >30 g/L indicates an exudate .

Indeterminate Range (25–35 g/L): In effusions where total protein falls between 25 and 35 g/L, gross protein cut-offs are unreliable. Light's criteria must be applied to definitively differentiate transudative from exudative pathology.

Etiological Distinctions

Transudative Causes (Systemic Mechanical Imbalance):

  • Congestive cardiac failure (most common transudate; elevated pulmonary capillary hydrostatic pressure)
  • Hepatic cirrhosis with hepatic hydrothorax (peritoneal fluid translocating across diaphragmatic defects)
  • Nephrotic syndrome (severe hypoalbuminemia reducing intravascular oncotic pressure)
  • Peritoneal dialysis
  • Hypoalbuminemia / severe protein-losing enteropathy
  • Constrictive pericarditis and superior vena cava obstruction

Exudative Causes (Local Pleural or Microvascular Pathology):

Parapneumonic effusions and bacterial empyema

Malignancy (bronchogenic carcinoma, metastatic adenocarcinoma of breast/ovary/GI tract, malignant pleural mesothelioma)

  • Pulmonary infarction secondary to pulmonary embolism
  • Autoimmune connective tissue diseases: Rheumatoid arthritis, systemic lupus erythematosus (SLE)
  • Tuberculosis (TB pleurisy)
  • Acute or chronic pancreatitis
  • Post-cardiac injury syndrome (Dressler's syndrome)
  • Benign asbestos pleural effusion
  • Drug-induced pleuritis (amiodarone, nitrofurantoin, methotrexate, dasatinib)
  • 2. Light's Criteria & Pleural Fluid Biochemistry

Light's criteria exhibit a sensitivity approaching 98% for identifying exudates, though specificity is approximately 83%.

Light's Criteria Table

  • Diagnostic Parameter Exudate Threshold
  • Pleural Fluid Protein to Serum Protein Ratio > 0.5
  • Pleural Fluid LDH to Serum LDH Ratio > 0.6
  • Pleural Fluid LDH > 2/3 the laboratory upper limit of normal (ULN) for serum LDH

An effusion is formally classified as an exudate if at least one of the three criteria is fulfilled. If none of the criteria are met, the effusion is a transudate .

The Pseudo-Exudate Trap: In patients with congestive cardiac failure who are actively receiving loop diuretic therapy, water is cleared from the pleural space more rapidly than macromolecules. This concentrates pleural protein and LDH, causing Light's criteria to misclassify a transudate as an exudate. In this clinical scenario, calculate the serum-to-pleural albumin gradient : Albumin Gradient = Serum Albumin − Pleural Fluid Albumin \text{Albumin Gradient} = \text{Serum Albumin} - \text{Pleural Fluid Albumin} Albumin Gradient = Serum Albumin − Pleural Fluid Albumin If the gradient is >12 g/L , the effusion is confirmed to be a transudate , and costly investigations for malignancy or infection can be safely averted.

High-Yield Pleural Fluid Biochemical Parameters

Fluid Parameter Clinical Significance & Typical Values

pH • Normal: ~7.60.; • pH <7.20: Indicates intense bacterial metabolism and local lactic acidosis. In parapneumonic effusion, pH <7.20 is an absolute indication for urgent intercostal chest drain placement .; • Non-infectious causes of pH <7.20: Rheumatoid pleurisy, systemic acidosis, esophageal rupture, severe tuberculous pleuritis, advanced malignancy.

Glucose • Normal: Parallels serum levels (ratio ~1.0).; • Markedly low (<1.6 mmol/L): Classically seen in rheumatoid pleuritis (often undetectable due to selective block in glucose transport across inflamed pleura), empyema, and esophageal rupture.; • Low (1.6–3.3 mmol/L): Tuberculous pleurisy, lupus pleuritis, complicated parapneumonic effusion, malignant effusion.

Amylase • Elevated (pleural/serum ratio >1.0 or pleural > upper limit of normal serum amylase): ; 1. Acute pancreatitis or pancreatic pseudocyst (pancreatic isoamylase).; 2. Esophageal rupture / Boerhaave's syndrome (salivary isoamylase leaking into left pleural space; accompanied by pH <6.0 and food particles).; 3. Malignancy (adenocarcinoma of lung or ovary).

Cytology & Differential • Neutrophilic predominance (>50%): Acute inflammatory processes (parapneumonic effusion, acute pulmonary embolism, pancreatitis).; • Lymphocytic predominance (>50%): Malignancy, tuberculosis, sarcoidosis, chronic rheumatoid pleurisy, chylothorax.; • Cytology Yield: Initial thoracentesis identifies malignant cells in ~60% of malignant effusions; repeat pleural tap increases yield to ~75%.

Adenosine Deaminase (ADA) • ADA >40 U/L: High sensitivity and specificity for tuberculous pleurisy , particularly in endemic settings or young patients with lymphocytic exudates.

Hematocrit • Pleural hematocrit >50% of peripheral blood hematocrit: Diagnostic of hemothorax (mandates large-bore chest tube insertion and urgent thoracic surgical consultation).

3. Pneumothorax: Pathophysiology & Classification

A pneumothorax occurs when gas accumulates within the pleural cavity, uncoupling the visceral and parietal pleura and collapsing the underlying lung parenchyma.

Primary Spontaneous Pneumothorax (PSP): Occurs in individuals with no clinically apparent underlying parenchymal lung disease . Classically affects tall, slender young males (aged 15–35 years) due to increased negative intrapleural pressures at the lung apices causing formation and rupture of subpleural apical blebs or bullae. Cigarette smoking increases the risk up to 20-fold.

Secondary Spontaneous Pneumothorax (SSP): Occurs as a complication of pre-existing lung pathology . Most frequently seen in patients >50 years with chronic obstructive pulmonary disease (COPD; rupture of emphysematous bullae), cystic fibrosis, idiopathic pulmonary fibrosis, severe asthma, Pneumocystis jirovecii pneumonia (in HIV/AIDS), thoracic endometriosis (catamenial pneumothorax), or necrotizing lung infections. Patients with SSP have markedly compromised physiological reserve and tolerate even small pneumothoraces poorly.

4. British Thoracic Society (BTS) Management Algorithms

On an erect posterior-anterior (PA) chest radiograph, the size of a pneumothorax is measured as the distance between the lung margin (visceral pleura) and the inner chest wall at the level of the hilum:

Small Pneumothorax: Visible rim of air <2 cm at the hilum.

Large Pneumothorax: Visible rim of air >=2 cm at the hilum (a 2 cm rim corresponds to approximately 50% volume collapse of the hemithorax).

BTS Spontaneous Pneumothorax Management Summary

Classification Clinical Presentation & Radiographic Size BTS Recommended Management Pathway

Primary Spontaneous Pneumothorax (PSP) Rim < 2 cm AND NOT breathless • Conservative management. Do not intervene.; • Discharge home with explicit written red flag advice; outpatient review with repeat CXR in 1–2 weeks.

Primary Spontaneous Pneumothorax (PSP) Rim >= 2 cm OR Breathless • Simple needle aspiration using a 16–18G cannula (aspirate up to 2.5 L).; • If aspiration succeeds (rim <2 cm and dyspnoea resolves): Observe for 2–4 hours; if stable, discharge home with early outpatient follow-up.; • If aspiration fails (still >=2 cm or breathless): Insert a small-bore chest drain (12–14 Fr) and admit to hospital.

Secondary Spontaneous Pneumothorax (SSP) Rim > 2 cm OR Breathless • Immediate intercostal chest tube insertion (12–14 Fr) and admit to hospital.; • Do not perform needle aspiration.

Secondary Spontaneous Pneumothorax (SSP) Rim 1–2 cm AND NOT breathless • Attempt needle aspiration with 16–18G cannula (limit to 1–2 L).; • If successful (reduces to <1 cm): Admit to hospital for observation and supplemental oxygen.; • If aspiration fails: Insert small-bore chest tube (12–14 Fr).

Secondary Spontaneous Pneumothorax (SSP) Rim < 1 cm AND NOT breathless • Admit to hospital for observation and high-flow oxygen therapy (maintain SaO2 94–98% unless at risk of hypercapnia in COPD, where target is 88–92%).; • Repeat CXR at 24 hours.

Tension Pneumothorax: Emergency Decompression

Tension pneumothorax develops when a one-way tissue valve mechanism permits air entry into the pleural cavity during inspiration but prevents egress during expiration. Intrapleural pressure becomes positive, collapsing the ipsilateral lung, shifting mediastinal structures and trachea to the contralateral side, kinking the superior and inferior vena cava, and precipitating immediate hemodynamic arrest.

Diagnosis: Strictly a clinical emergency diagnosis —never delay management to obtain a chest radiograph!

Clinical Signs: Severe respiratory distress, cyanosis, tracheal deviation away from the affected side, hyper-resonance, absent breath sounds on the affected side, distended neck veins, and profound hypotension.

Immediate Intervention: Emergency decompression via a large-bore cannula (14–16G) inserted into the 2nd intercostal space in the mid-clavicular line (or 4th/5th intercostal space anterior axillary line) on the affected side. A hiss of escaping pressurized air confirms decompression. This must be followed immediately by formal intercostal chest drain insertion into the safe triangle (5th intercostal space mid-axillary line).

Aviation & Scuba Diving Advice (High Exam Yield)

Commercial Air Travel: Patients must not fly until at least 1 to 2 weeks following complete radiographic re-expansion of the pneumothorax. Cabin pressure drops to equivalent altitudes of 8,000 feet, causing trapped air pockets to expand by ~30% (Boyle's law: P 1 V 1 = P 2 V 2 P_1V_1 = P_2V_2 P 1 ​ V 1 ​ = P 2 ​ V 2 ​ ), risking tension pneumothorax.

Scuba Diving: Diving is permanently contraindicated following a spontaneous pneumothorax due to the catastrophic risk of tension pneumothorax and arterial gas embolism during ascent. The only exception is if the patient has undergone definitive bilateral surgical pleurectomy and demonstrates completely normal baseline post-operative thoracic CT imaging and full pulmonary function testing.